A rapid, point-of-care red blood cell agglutination assay detecting antibodies against SARS-CoV-2.

ABSTRACT: The COVID-19 pandemic has caused significant morbidity and mortality. There is an urgent need for serological tests to detect antibodies against SARS-CoV-2, which could be used to assess past infection, evaluate responses to vaccines in development, and determine individuals who may be protected from future infection. Current serological tests developed for SARS-CoV-2 rely on traditional technologies such as enzyme-linked immunosorbent assays (ELISA) and lateral flow assays, which have not scaled to meet the demand of hundreds of millions of antibody tests so far. Herein, we present an alternative method of antibody testing that depends on one protein reagent being added to patient serum/plasma or whole blood with direct, visual readout. Two novel fusion proteins, RBD-2E8 and B6-CH1-RBD, w

SUBMITTER: Kruse RL 

PROVIDER: S-EPMC7959259 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature